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Introduction: HIV/HCV coinfection is a risk factor for hepatic injury in patients receiving HAART and previous studies support a
favourable effect of antiretroviral regimens including maraviroc (MVC) on the course of coinfection compared with other
antiretroviral drugs. There are few observations about MVC use in simplified treatment of coinfected patients.Objective: To
evaluate the efficacy and the safety of simplification to darunavir (DRV)/ritonavir (r)/maraviroc (MVC) in virologically HIV-
suppressed patients and to explore the effect of simplified treatment on coinfected patients.
Materials and Methods: GUSTA study is a randomized two arms trial that compares the switch to DRV/r/MVC with standard
HAART with three drugs. The study enrols patients with HIV-1 RNAB50cp/mL6 months, R5 tropism, CD4200 cells/mm.
Survival analysis was used to analyze factors associated to time-to a single viral load (VL) over 50cp/mL and FIB-41.45.
Results: We included 62 patients with at least the 24 week follow-up for FIB-4 analysis: males 75.8%, heterosexuals 48.4%,
HCV12.9% median age 48.3 years (IQR41.1;53.5), time from HIV diagnosis 11.0 years (IQR7.3;16.7), CD4 cells 659/mm
(IQR478;882), nadir CD4 203/mm (IQR115;286), FPR 46 (IQR30;70), baseline (BL) FIB-4 1.11 (IQR0.75;1.35). At BL no differences
were observed in the two arms, except for platelets (34.96 109/L, in the study arm, p0.028) and CD4 at nadir (70cell/mL,
p0.051). After 24 weeks a significant reduction in total bilirubin (TB) (0.55 mg/dL, p0.025) and alkaline phosphatase(AP)
(12.96 UI/L, p0.002) was observed in the study group. A statistically significant difference in mean change of TB (0.61 mg/
dL, p0.016) and AP (13.23 UI/L, p0.04) at 24 week between control and study group was observed. No grade 3/4
transaminase elevation was observed for any patient even if HIV/HCV coinfected and receiving MVC. A single HCV negative
patient in the control arm had grade 3 bilirubin increase. Including all patients with at least one follow-up HCV status was not
associated with an increased risk of detectable VL (n114, 4072 person-week-follow-up [IQR12;51.6]), nor with FIB-41.45
(n98, 3513 person-week-follow-up [IQR11.4;50.9]).
Conclusion: The initial results from GUSTA study show that ART-regimen including MVC did not increase the incidence of adverse
events or severe laboratory liver abnormalities in HIV-1-infected patients with or without HCV coinfection. Coinfected patients
did not show an increased risk of failure on simplification treatment with MVC/DRV/r.
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Table 1. Factors associated with FIB-41.45 at Cox regression analysis
Univariate analysis Multivariate analysis
Factors associated with FIB-41.45 at Cox regression
analysis HR CI p HR CI p
Boosted protease inhibitors previous use 2.554 0.853; 7.648 0.094 1.315 0.413; 4.185 0.643
Raltegravir previous 3.896 1.133; 13.405 0.031 6.122 1.278; 29.328 0.023
BL FIB-4 74.08 7.91; 694.18 B0.001 129.232 9.792; 1705.564 B0.001
Hcv positive 1.011 0.275; 3.713 0.986 0.485 0.112; 2.103 0.334
Study group 2.086 0.839; 5.185 0.113 0.958 0.354; 2.589 0.932
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